• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Striving For Diversity In Clinical Trials

Striving For Diversity In Clinical Trials

May 2, 2007
CenterWatch Staff

AstraZeneca has launched a new initiative to address the lack of diversity in U.S. clinical trial participants. The big pharma company will provide significant grants to the National Medical Association (NMA), which represents more than 30,000 African American physicians, and the Interamerican College of Physicians and Surgeons (ICPS), a network of more than 39,000 physicians throughout the U.S. and Puerto Rico.

AstraZeneca expects that its ongoing partnership with NMA and ICPS will ensure that physicians of diverse backgrounds receive the education and tools they need to participate as investigators in clinical trials.

Several top-20 pharmaceutical companies have approached the challeng getting racial and ethnic diversity in their study groups by trying to engage a more racially diverse group of investigators or those with access to diverse patient populations. These have mostly been internal initiatives. AstraZeneca’s decision to partner with these well-established organizations is a new approach to gaining access to African American and Hispanic patient populations and one that could lead to some real success.

Alfonso Alanis, M.D., chairman and chief executive officer of Anaclim, a minority-focused contract research organization (CRO), said, “One of the key reasons minorities do not participate in clinical trials is that they are not invited. Their physicians do not participate.”

Anaclim has created a database of about 1400 investigators with access to minority populations.

African American and Hispanic populations continue to grow as a proportion of the U.S. population and, in some diseases, have higher incidence rates than caucasians, according to the Centers for Disease Control. Industry needs to study these groups in proportionate numbers in clinical trials to complete safety and efficacy profiles and to be able to market their drugs to these groups.

Increasing participation of racial and ethnic minorities in clinical trials requires a multi-pronged approach. AstraZeneca’s partnership with NMA and ICPS is a step in the right direction, but there is much to do still to get the clinical trial participant population to reflect the U.S. population overall.

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing